The disclosure uses, but is not limited to, a therapeutically effective amount of an RNAi agent for KRAS, including but not limited to solid or liquid cancer, adenocarcinoma, colorectal cancer, advanced and / or metastatic colorectal cancer, colon cancer, Lung cancer, non-small cell lung cancer and lung adenocarcinoma, acute myeloid lung cancer, bladder cancer, brain tumor, breast cancer, cervical cancer, endometrial cancer, stomach cancer, head and neck cancer, kidney cancer, leukemia, myelodysplastic syndrome Proliferative, such as, myeloid leukemia, liver cancer, melanoma, ovarian cancer, pancreatic cancer, prostate cancer, testicular cancer, thyroid cancer, and Cardio-Facio-Cutaneous (CFC) syndrome and Noonan syndrome, and similar and related diseases It relates to RNAi agents useful in methods of treating KRAS-related diseases such as diseases.本開示は、治療有効量のＫＲＡＳに対するＲＮＡｉ剤を用いる、限定されるものではないが、固形または液性癌、腺癌、結腸直腸癌、進行性および／または転移性結腸直腸癌、結腸癌、肺癌、非小細胞肺癌および肺腺癌、急性骨髄性肺癌、膀胱癌、脳腫瘍、乳癌、子宮頸癌、子宮内膜癌、胃癌、頭部および頸部癌、腎臓癌、白血病、骨髄異形成症候群、骨髄性白血病、肝臓癌、黒色腫、卵巣癌、膵臓癌、前立腺癌、精巣癌、甲状腺癌、およびＣａｒｄｉｏ－Ｆａｃｉｏ－Ｃｕｔａｎｅｏｕｓ（ＣＦＣ）症候群およびヌーナン症候群、ならびに類似および関連する疾患などの増殖性疾患のようなＫＲＡＳ関連疾患を処置する方法において有用なＲＮＡｉ剤に関する。
